Mehta, D., Raison, C. L., Woolwine, B. J., Haroon, E., Binder, E. B., Miller, A. H., & Felger, J. C. (2013). Transcriptional Signatures Related to Glucose and Lipid Metabolism Predict Treatment Response to the Tumor Necrosis Factor Antagonist Infliximab in Patients with Treatment-Resistant Depression.

Mehta, Divya, Charles L. Raison, Bobbi J. Woolwine, Ebrahim Haroon, Elisabeth B. Binder, Andrew H. Miller, and Jennifer C. Felger. Transcriptional Signatures Related to Glucose and Lipid Metabolism Predict Treatment Response to the Tumor Necrosis Factor Antagonist Infliximab in Patients With Treatment-Resistant Depression. 2013.

Mehta, Divya, et al. Transcriptional Signatures Related to Glucose and Lipid Metabolism Predict Treatment Response to the Tumor Necrosis Factor Antagonist Infliximab in Patients With Treatment-Resistant Depression. 2013.